Glidiab

Глидиаб Drug photo

The description is actual on 30.10.2015

  • Latin name: Glidiab
  • ATH code: A10BB09
  • Active ingredient: Gliklazid (Gliclazide)
  • Producer: JSC Akrikhin (Russia)

Structure

1 tablet includes 80 mg of a gliklazid. In addition: milk sugar, hydromagnesium silicate, microcrystallic cellulose, a gidroksipropilmetiltsellyuloza, potato starch, sodium krakhmalglikolit, magnesium stearate.

1 tablet MR (the modified release) includes 30 mg of a gliklazid. In addition: gidroksipropilmetiltsellyuloza, aerosil, microcrystallic cellulose, magnesium stearate.

Release form

Drug Glidiab is made in the form of tablets on 80 mg No. 60 and tablets MV on 30 mg No. 30 or No. 60 in secondary packaging.

Pharmacological action

(Hypoglycemic) lowering sugar level.

Pharmacodynamics and pharmacokinetics

Gliklazid is the peroral hypoglycemic medicine relating to derivatives of a sulfonilmochevina of the 2nd generation. Effect of drug directionally on activation of the β-cells in a pancreas producing insulin, increase in a susceptibility to it peripheral fabrics, strengthening of insulinosekretorny effects of glucose and stimulation of activity of an intracellular glikogensintetaza in muscular tissue. Drug reduces the time period from the moment of receipt of food prior to production of insulin, reduces the postprandialny level of glucose, and also recovers early (first) peak of insulin secretion (unlike the other drugs of a sulfonilmochevina which are mainly operating in the second phase).

Except adjustment of carbohydrate metabolism gliklazid improves microcirculation, by means of reduction of platelet aggregation and adhesion, normalization of vascular permeability, recovery of physiological process of a pristenochny fibrinolysis.

Therapy using Glidiab reduces sensitivity of vessels to adrenaline influence, interferes with forming of atherosclerosis and microthrombosis. Slows down progressing of not proliferative (background) diabetic retinopathy. At prolonged treatment reliable reduction of the proteinuria developing against a diabetic nephropathy is observed.

Administration of drug, because of its influence on an early stage of secretion of insulin, is not followed by increase in weight and even favors to its decrease at corpulent patients, in case of observance of the corresponding dietotherapy.

Oral administration of a gliklazid leads to its actually full absorption in a gastrointestinal tract. TCmax in blood serum makes 4 hours (for tablets MV – 6-12 hours). Linkng with plasma proteins is at the level of 90-95%. Metabolic transformations happen in a liver to allocation of inactive products of a metabolism. T1/2 makes 8-11 hours (for tablets MV – 16 hours). Removal in the form of metabolites is carried out mainly by kidneys (about 70%), and also intestines (12%). About 1% of a gliklazid is excreted in an invariable view with urine.

Indications to use

Glidiab's use is shown at treatment of a diabetes mellitus of the 2nd type (INSD, non-insulin-dependent diabetes) with in parallel the carried-out dietotherapy and performance of exercise stresses of moderate complexity, in case of their inefficiency in the past.

Contraindications

Glidiab's reception is absolutely contraindicated at:

  • diabetic ketoacidosis;
  • feeding by a breast;
  • diabetes mellitus of the 1st type;
  • diabetic prekome / to a coma;
  • heavy pathologies of livers/kidneys;
  • to giperosmolyarny coma;
  • leukopenias;
  • painful states, with need of use of insulin, including injuries, surgeries, extensive burns;
  • stomach paresis;
  • pregnancies;
  • intestinal impassability;
  • the pathologies which are followed by malabsorptions of food and forming of a hypoglycemia (including infectious diseases);
  • personal hypersensitivity to a gliklazid or other components of HP;
  • at children's age.

Carefully (carefully selecting dosages and conducting regular examinations) it is necessary to appoint Glidiab at:

Side effects

The most widespread and heavy by-effect of Glidiab is the hypoglycemia most often arising at disturbances of the dosing mode and inadequate dietotherapy. The symptomatology of this complication is quite various and can be shown: headaches, feeling of hunger, feeling of fatigue, the sudden weakness, a carelessness, uneasiness, aggression, irritability, depressions which is slowed down by reaction, impossibility to concentrate, vision disorders, feeling of helplessness, aphasia, touch frustration, a tremor, dizziness, a delirium, self-checking loss, spasms, a loss of consciousness, hypersomnia, shallow breathing, perspiration, bradycardia.

The negative phenomena observed from a gastrointestinal tract which are expressed by dyspepsia are considered as plug effects of therapy by Glidiab, the second for the importance, (nausea, weight in epigastriums and diarrhea); disturbances of hepatic function (increase in activity of transaminases of a liver, cholestatic jaundice); anorexia (in case of reception of tablets together with food expressiveness of anorexia decreases).

Also the allergic manifestations which are generally consisting in developing of urticaria, makulo-papular rash and skin itch can develop.

Sometimes observed forming of a leukopenia, thrombocytopenia and anemia.

Glidiab, application instruction

Selection of the dosing mode of drug Glidiab is carried out in an individual order according to clinical manifestations by INSD and level of a glycemia which is measured on an empty stomach, and also after 2 hours after food.

Initially recommend daily reception of the 1st tablet of Glidiab of 80 mg or the 1st tablet of Glidiab of MV of 30 mg. The average daily dosage is equal 160 mg and 60 mg, and maximum – 320 mg and 120 mg, respectively for tablets and tablets MV. A usual pill of Glidiab of 80 mg is taken in 30-60 minutes prior to food twice at 24 o'clock (in the morning and in the evening). Tablets MV of 30 mg are shown to be accepted once every morning during a breakfast. Increase in doses it is possible to spend not less than 14 days with an interval.

Elderly patients and patients with pathologies of kidneys (at KK of 15-80 ml/min.) do not need correction of doses.

Overdose

At overdose gliklazidy observed development of the hypoglycemia sometimes reaching a hypoglycemic coma.

In a case when symptoms of overdose allow the patient to be in consciousness, he needs to drink immediately solution of sugar or glucose (dextrose). At an unconsciousness of the patient, it is shown in/in administration of solution of the Dextrose (40%) or an injection of the Glucagon in oil (1-2 mg). Further, at some normalization of a state, the patient should eat products with high content of carbohydrates, for the purpose of the prevention of recurrence of a hypoglycemia.

Interaction

Decrease in hypoglycemic efficiency of Glidiab is observed in case of its parallel use with glucocorticoids, barbiturates, sympathomimetics (Terbutalin, Epinephrinum, Ritodrinum, the Clonidine, Salbutamol), antagonists of calcium, lithium salts, niacin, thiazide diuretics, inhibitors of a karboangidraza (Diacarbum), Chlortalidonum, Triamterenum, Chlorpromazinum, Furosemide, Asparaginase, Danazol, Baclofenum, Diazoxide, Rifampicin, Morphine, the Isoniazid, the Glucagon, Phenytoinum, hormones of a thyroid gland and estrogen (including oral contraceptives).

Increase of hypoglycemic activity of Glidiab is noted at its combined use with antifungal HP (Flukonazol, Miconazolum), APF inhibitors (Enalapril, Captopril), H2 blockers (Cimetidinum), fibratam (Bezafibrat, Clofibratum), NPVS (Indometacin, Phenylbutazone, Diclofenac), salicylates, antituberculous remedies (Etioniamidum), indirect anticoagulants, β-adrenoblockers, the anabolic steroids, Cyclophosphamide, MAO inhibitors, Chloramphenicol, Theophylline, Allopyrinolum prolonged by streptocides, Fenfluramin, Pentoksifillin, Fluoxetine, Guanetidin, Reserpinum, locks of canalicular secretion, Disopyramidum, Bromocriptinum, the Pyridoxine, ethanol and also with other hypoglycemic HP (insulin, guanyl guanidines, an akarboza).

Joint reception of Glidiab and cardiac glycosides increases risk of forming of a ventricular ekstrasistoliya.

Effects of β-adrenoblockers, Reserpinum, the Clonidine, Guanetidin can hide clinical symptomatology of a hypoglycemia.

Terms of sale

Glidiab in any dosage form treats prescription medicines.

Storage conditions

The maximum temperature of storage of tablets and Glidiab tablets MV – 25 °C.

Period of validity

For usual tablets – 4 years.

For tablets MV – 2 years.

Special instructions

Treatment by Glidiab should be carried out with assistance of a low-calorie dietotherapy with the minimum inclusion of carbohydrates.

Deviations in a diet, and also an emotional and physical overstrain demand correction of dosages of a gliklazid.

Throughout therapy it is necessary to exercise control over glycemia level, checking it on an empty stomach and after food.

At SD decompensation, and also surgical interventions it is necessary to consider possible purpose of insulinosoderzhashchy drugs.

The patient has to be informed on a possibility of forming of a hypoglycemia at starvation, reception of NPVS and etanolsozherzhashchy drugs.

Special sensitivity to effects of hypoglycemic drugs is shown by the elderly patients weakened patients, or those which do not receive the balanced food, and also the people suffering from a hypocorticoidism.

It is necessary to treat with care performance of dangerous or exact works, and also driving of the car, in particular during selection of the dosing mode, because of the increased risk of forming of a hypoglycemia.

Analogs

Zdravzona

  • Glidiab of 80 mg No. 60 tabletkiakrikhin HFK of joint stock company
  • Glidiab of MV of 30 mg No. 60 tabletkiakrikhin HFK of joint stock company

Drugstore of IFC

  • Glidiab tbl 80 mg No. 60, HFK (г.Москва) Russia Quinacrine
  • Glidiab of MV tbl 30 mg No. 60, HFK (г.Москва) Russia Quinacrine
to show still
Section: Diabetic
in more detail

Education: Graduated from the Vinnytsia national medical university of N. I. Pirogov, pharmaceutical faculty, the higher pharmaceutical education – the specialty "Pharmacist".

Experience: Work in Koneks and Bios-Media pharmacy chains as "Druggist". Work as "Pharmacist" in Avicenna pharmacy chain of the city of Vinnytsia.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Glidiab surely consult with the attending physician.